In fact, KRAS variants are identified in 90% to 92% of patients with PDAC; hence, the possibility of assessing genetic mutations using a non-invasive analysis of human biospecimens is encouraging, both for the early diagnosis of pancreatic cancer (PC) and for the identification of precancerous lesions [1,6,7]. Here, KRAS is linked to pancreatic neoplasm.